Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FGF-5 Peptide Vaccine in Renal Cancer
NCT00089778Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Aug 2008
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of FGF-5 peptide vaccine in renal cell carcinoma (RCC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate, Count of Participants With Adverse Events at 47 months and 1 more. Started Sep 2004; status: terminated.
02
Drugs
FGF-5 peptide vaccine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00089778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089778.